Senzime AB (SEZI):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Senzime AB (SEZI) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7503
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Senzime AB (Senzime) is a medical device company that develops patient-oriented monitoring systems. The company’s product include TetraGraph monitor, CliniSenz analyzer, and Onzurf probe. Its TetraGraph monitor stimulates, measures, analyzes and displays muscle function in surgical patients receiving neuromuscular blocking agents. Senzime’s portfolio of technologies includes bedside systems that enable automated and continuous measurement of biological substances such as glucose and lactate in the blood and tissue fluid and patient-system for peri-operative monitoring of the neuromuscular function in patients undergoing depth of anesthesia. The company’s products are used in the areas of medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. Senzime is headquartered in Uppsala, Sweden.

Senzime AB (SEZI) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Senzime AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Senzime AB, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Senzime AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Senzime AB, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Senzime AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Senzime AB, Medical Equipment, Deal Details 10
Private Equity 10
Senzime to Raise USD3.1 Million in Private Placement of Shares 10
Partnerships 11
Senzime Enters into Licesning Agreement with Fukuda Denshi 11
Senzime Enters into Distribution Agreement with Wardray Premise and LSR Healthcare 12
Equity Offering 13
Senzime Raises USD2.7 Million in Rights Offering of Shares 13
Senzime Raises USD0.3 Million in Private Placement 14
Senzime Raises USD2 Million in Rights Offering of Shares 15
Senzime Raises USD7 Million in Private Placement 16
Senzime Raises USD1.15 Million in Private Placement of Shares 17
Senzime Raises USD2.8 Million in Rights Offering of Shares 18
Senzime to Raise USD1.9 Million in Rights Offering of Shares 19
Senzime Raises USD1 Million in Rights Offering of Common Shares 20
Acquisition 21
Senzime Acquires Acacia Designs for USD10.2 Million 21
Senzime Acquires MD Biomedical 22
Senzime AB – Key Competitors 23
Senzime AB – Key Employees 24
Senzime AB – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 22, 2018: Senzime: Interim report quarter 2, 2018 26
May 08, 2018: Senzime’s Interim report January – March 2018 27
Feb 16, 2018: Senzime’s Year-end Bulletin 2017 28
Nov 28, 2017: Senzime’s Interim report January – September 2017 29
Aug 31, 2017: Senzime’s Interim report January – June 2017 30
May 31, 2017: Senzime’s Interim report January – March 2017 31
Legal and Regulatory 33
Jun 12, 2017: Senzime receives ISO 13485 certification 33
Feb 07, 2017: Senzime launches new website 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Senzime AB, Medical Equipment, Key Facts, 2017 2
Senzime AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Senzime AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Senzime AB, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Senzime AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Senzime AB, Deals By Market, 2012 to YTD 2018 8
Senzime AB, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Senzime to Raise USD3.1 Million in Private Placement of Shares 10
Senzime Enters into Licesning Agreement with Fukuda Denshi 11
Senzime Enters into Distribution Agreement with Wardray Premise and LSR Healthcare 12
Senzime Raises USD2.7 Million in Rights Offering of Shares 13
Senzime Raises USD0.3 Million in Private Placement 14
Senzime Raises USD2 Million in Rights Offering of Shares 15
Senzime Raises USD7 Million in Private Placement 16
Senzime Raises USD1.15 Million in Private Placement of Shares 17
Senzime Raises USD2.8 Million in Rights Offering of Shares 18
Senzime to Raise USD1.9 Million in Rights Offering of Shares 19
Senzime Raises USD1 Million in Rights Offering of Common Shares 20
Senzime Acquires Acacia Designs for USD10.2 Million 21
Senzime Acquires MD Biomedical 22
Senzime AB, Key Competitors 23
Senzime AB, Key Employees 24
Senzime AB, Other Locations 25
Senzime AB, Subsidiaries 25

List of Figures
Senzime AB, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Senzime AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Senzime AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Senzime AB, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Senzime AB, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Senzime AB, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Senzime AB, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Senzime AB, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Senzime AB (SEZI):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ILF Consulting Engineers:企業の戦略・SWOT・財務情報
    ILF Consulting Engineers - Strategy, SWOT and Corporate Finance Report Summary ILF Consulting Engineers - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • UNIQA Romania:企業の戦略・SWOT・財務情報
    UNIQA Romania - Strategy, SWOT and Corporate Finance Report Summary UNIQA Romania - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Kentucky Power Co:企業の戦略的SWOT分析
    Kentucky Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Golden Meditech Holdings Ltd (801):製薬・医療:M&Aディール及び事業提携情報
    Summary Golden Meditech Holdings Ltd (Golden Meditech) is a medical equipment provider that provides blood stem cells storage and hospital management solutions. The company provides autologous blood recovery systems. It offers hospital management, medical insurance administration and blood bank serv …
  • ContraFect Corp (CFRX):製薬・医療:M&Aディール及び事業提携情報
    Summary ContraFect Corp (ContraFect) is a clinical stage biotechnology company that discovers and develops therapeutic protein and antibody products. The company develops products using lysin and monoclonal antibody platforms for the treatment of life threatening, drug-resistant infectious diseases. …
  • Northrop Grumman Corp (NOC):企業の財務・戦略的SWOT分析
    Northrop Grumman Corp (NOC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Universal Health Services Inc (UHS):製薬・医療:M&Aディール及び事業提携情報
    Summary Universal Health Services Inc (UHS) is a healthcare service provider the offers acute care and behavioral health services. The center provides services such as general and specialty surgery, internal medicine, obstetrics, oncology, diagnostic care, coronary care, emergency room care, radiolo …
  • Entasis Therapeutics Inc (ETTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Entasis Therapeutics Inc (Entasis) is a drug development company that discovers and develops anti-infective therapies for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, ETX0282, ETX0914 and Zoliflodacin. Its ETX2514 is a potent inhibitor of class A, C, …
  • Charles River Laboratories International Inc (CRL):企業の財務・戦略的SWOT分析
    Charles River Laboratories International Inc (CRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • STATS ChipPAC Pte Ltd:企業の戦略的SWOT分析
    STATS ChipPAC Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • MIS Implants Technologies Ltd-医療機器分野:企業M&A・提携分析
    Summary MIS Implants Technologies Ltd (MIS) is a medical device company that offers advanced products and solutions for dental implantology treatment. The company offers dental implants, tools and kits, superstructures, and solutions for oral restoration and health, among others. Its implants compri …
  • Aegis Therapeutics LLC-製薬・医療分野:企業M&A・提携分析
    Summary Aegis Therapeutics LLC (Aegis Therapeutics) is a biotechnology company that research and develops drug delivery and drug formulation technologies. The company commercializes new drug delivery and protein stabilization technologies through product specific licenses to pharmaceutical and bioph …
  • Syngenta AG:企業の戦略的SWOT分析
    Syngenta AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Olmuksan International Paper Ambalaj Sanayi ve Ticaret A.S.:企業の戦略・SWOT・財務情報
    Olmuksan International Paper Ambalaj Sanayi ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report Summary Olmuksan International Paper Ambalaj Sanayi ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers th …
  • Toagosei Co Ltd (4045):企業の財務・戦略的SWOT分析
    Toagosei Co Ltd (4045) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Revolution Lighting Technologies Inc (RVLT):企業の財務・戦略的SWOT分析
    Revolution Lighting Technologies Inc (RVLT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Kian Joo Can Factory Berhad:戦略・SWOT・企業財務分析
    Kian Joo Can Factory Berhad - Strategy, SWOT and Corporate Finance Report Summary Kian Joo Can Factory Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Theraclion SA (ALTHE):企業の財務・戦略的SWOT分析
    Summary Theraclion SA (Theraclion) is a medical device company that designs, markets, and develops high-intensity focused therapeutic ultrasound devices and equipment; and offers technical support services. The company offers echotherapy solution that combines HIFU therapy with ultrasound as a syste …
  • Activision Blizzard Inc (ATVI):企業の財務・戦略的SWOT分析
    Activision Blizzard Inc (ATVI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Circle Pharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary Circle Pharma Inc. (Circle Pharma) is a drug development company that strives to develop cell permeable macrocyclic peptide therapies by combining computational design and synthetic chemistry. Its technology platform is applicable in a wide range of disease conditions such as fibrosis, infla …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆